Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | LY3023414 | 0.006658349 | -0.1896 | 0.6194 | 2.1680 | -0.4984 | 0.1195 | 0.4950 | 0.000195378 |
| BT-549 | MK 1775 | 0.285141860039 | -0.4630 | 0.4365 | 2.2824 | -1.0000 | 0.5282 | 0.9608 | 1.11022302463e-16 |
| HCC1806 | AZD2014 | 1.79837045193 | 0.3811 | 0.3438 | 2.3555 | -0.0311 | 0.2238 | 0.8823 | 2.43538522682e-12 |
| MDA-MB-157 | LY3023414 | 0.120671918 | -0.4605 | 0.5635 | 2.6226 | -1.0000 | 0.3568 | 0.8702 | 8.21e-12 |
| T47D | BMS-265246 | 0.014946978 | -0.0154 | 0.6421 | 2.6347 | -0.7862 | 0.1827 | 0.8936 | 6.85e-13 |
| MCF 10A | Ulixertinib | 1.461707314 | 0.2159 | 0.2704 | 2.7171 | -0.1676 | 0.4662 | 0.9511 | 1.11e-16 |
| MDA-MB-361 | GSK2334470 | 0.050377803 | -0.4513 | 0.5704 | 2.8790 | -1.0000 | 0.2716 | 0.7322 | 7.05e-08 |
| HCC70 | GSK2334470 | 1.24076593852 | 0.1570 | 0.2931 | 2.9247 | -0.2245 | 0.4326 | 0.8858 | 1.66633373766e-12 |
| MDA-MB-134-VI | MK 1775 | 0.087205685 | -0.3434 | 0.5624 | 3.0209 | -1.0000 | 0.3099 | 0.7289 | 8.21e-08 |
| CAL-85-1 | MK 1775 | 0.182874423 | -0.5298 | 0.5409 | 3.0854 | -1.0000 | 0.3888 | 0.7205 | 1.2e-07 |
| SUM1315MO2 | GSK2334470 | 3.600228452 | 0.4232 | 0.3147 | 3.1371 | 0.0175 | 0.2587 | 0.5781 | 2.07e-05 |
| MDA-MB-468 | MK 1775 | 0.262235497 | -0.5155 | 0.4993 | 3.2089 | -1.0000 | 0.4387 | 0.8844 | 1.93e-12 |
| BT-20 | THZ531 | 1.39952715577 | 0.5663 | 0.0377 | 3.3807 | -1.0000 | 1.2457 | 0.6737 | 8.31588281125e-07 |
| AU565 | MK 1775 | 0.223405816 | -0.4543 | 0.4894 | 3.6482 | -1.0000 | 0.3933 | 0.8692 | 9.09e-12 |
| SUM1315MO2 | RO-3306 | 2.725021263 | -0.1710 | 0.2025 | 3.6560 | -0.3370 | 1.7529 | 0.8824 | 2.39e-12 |
| HCC1806 | AZD6738 | 1.14078689634 | -0.2827 | 0.2797 | 3.6562 | -0.8273 | 0.8382 | 0.9812 | 1.11022302463e-16 |
| HCC1428 | RO-3306 | 3.430055795 | -0.4441 | 0.0143 | 3.8909 | -0.2512 | 3.2292 | 0.3585 | 0.003891828 |
| HCC1143 | RO-3306 | 1.73126532 | -0.1079 | 0.2418 | 3.9460 | -0.5002 | 0.8416 | 0.9451 | 2.22e-16 |
| SUM1315MO2 | LY3023414 | 0.016412717 | -0.2854 | 0.6641 | 4.0058 | -1.0000 | 0.1998 | 0.8425 | 9.21e-11 |
| HCC1143 | MK 1775 | 0.667235616 | -0.4310 | 0.3475 | 4.0400 | -1.0000 | 0.6101 | 0.9306 | 3.33e-15 |
| HME1 | RO-3306 | 4.087843972 | -0.0172 | 0.0517 | 4.0640 | 0.0144 | 5.0000 | 0.9574 | 1.11e-16 |
| HCC1395 | Ulixertinib | 1.871580782 | 0.1659 | 0.2498 | 4.1054 | -0.2114 | 0.4489 | 0.7753 | 7.87e-09 |
| BT-20 | MK 1775 | 1.80498033053 | -0.6583 | 0.2015 | 4.1869 | -1.0000 | 1.3057 | 0.9322 | 2.44249065418e-15 |
| SUM159PT | AZD2014 | 0.175359057 | 0.0970 | 0.4747 | 4.2801 | -0.5797 | 0.2409 | 0.9735 | 1.11e-16 |
| MCF 10A | AZD2014 | 0.030975176 | -0.1702 | 0.6409 | 4.3568 | -1.0000 | 0.2221 | 0.9310 | 3.11e-15 |